KNSA logo

Kiniksa Pharmaceuticals International plc (KNSA)

$59.49

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on KNSA

Market cap

$4.58B

EPS

0.91

P/E ratio

59.7

Price to sales

5.49

Dividend yield

--

Beta

0.118927

Price on KNSA

Previous close

$57.13

Today's open

$57

Day's range

$56.50 - $59.94

52 week range

$26.27 - $59.94

Profile about KNSA

CEO

Sanj K. Patel

Employees

315

Headquarters

London,

Exchange

Nasdaq Global Select

Shares outstanding

76938016

Issue type

Common Stock

KNSA industries and sectors

Healthcare

Biotechnology & Life Sciences

News on KNSA

Biotech Kiniksa Pushes Toward A Buy Zone With Blockbuster Drug Sales In View

Biotech firm Kiniska is a standout with its profitability. The biotech stock is moving toward a buy zone amid a winning streak.

news source

Investors Business Daily • 19 hours ago

news preview

Here's Why Momentum in Kiniksa Pharmaceuticals International, plc (KNSA) Should Keep going

If you are looking for stocks that are well positioned to maintain their recent uptrend, Kiniksa Pharmaceuticals International, plc (KNSA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

news source

Zacks Investment Research • Jun 19, 2026

news preview

New Strong Buy Stocks for June 18th

TWFG, XPO, MUSA, FLYW and KNSA have been added to the Zacks Rank #1 (Strong Buy) List on June 18, 2026.

news source

Zacks Investment Research • Jun 18, 2026

news preview

Kiniksa Pharmaceuticals International, plc (KNSA) Upgraded to Strong Buy: Here's What You Should Know

Kiniksa Pharmaceuticals International, plc (KNSA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

news source

Zacks Investment Research • Jun 16, 2026

news preview

Kiniksa Pharmaceuticals International, plc (KNSA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Kiniksa Pharmaceuticals International, plc (KNSA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

news source

Seeking Alpha • Jun 10, 2026

news preview

Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

LONDON, May 29, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in fireside chats at the following investor conferences in June:

news source

GlobeNewsWire • May 29, 2026

news preview

Kiniksa: Increased Outlook For Arcalyst, Augmented By Pipeline Maturation

Kiniksa Pharmaceuticals continues to outperform, with Arcalyst net sales poised to surpass my previous bullish estimates. Arcalyst captured 18% of the recurrent pericarditis market by end-2025, with average therapy duration rising to three years and further upside from a new consumer awareness campaign. KPL-387, a next-generation IL-1 antibody, is set for phase 2 proof-of-concept data in H2 2026, offering improved economics and patient convenience compared to Arcalyst.

news source

Seeking Alpha • Apr 29, 2026

news preview

Why Kiniksa Pharmaceuticals International Stock Raced Nearly 24% Higher Today

Its Arcalyst has been on the market for years, yet it posted strong sales growth in the period. More is to come, apparently, as management raised its net sales guidance for the drug.

news source

The Motley Fool • Apr 28, 2026

news preview

Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2026 Earnings Call Transcript

Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2026 Earnings Call Transcript

news source

Seeking Alpha • Apr 28, 2026

news preview

Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution

– ARCALYST ® (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $930 - $945 million – – KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026; Phase 3 pivotal trial expected to initiate by year-end – – Q1 2026 cash balance increased to $468.1 million – – Conference call and webcast scheduled for 8:30 am ET today –

news source

GlobeNewsWire • Apr 28, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Kiniksa Pharmaceuticals International plc

Open an M1 investment account to buy and sell Kiniksa Pharmaceuticals International plc commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in KNSA on M1